What caused the pre-market volume surge in 4564.T stock?

Pre-market volume rose to **66,352,100.00** shares as traders reacted to clinical and liquidity concerns. Small-float biotech names like OncoTherapy often see outsized moves around trial updates and slot into the most active lists on JPX.

What is Meyka AI’s outlook for 4564.T stock this year?

Meyka AI's forecast model projects a yearly price of **JPY 17.31** for 4564.T stock, implying about **-17.57%** from **JPY 21.00**. These are model-based projections and do not guarantee future returns.

What key metrics should investors watch for 4564.T stock?

Watch EPS **-2.83**, PE **-8.13**, cash per share **JPY 6.06**, and clinical milestones. Also monitor volume vs. average **41,499,891.00** and sector news for quick price moves on JPX.

Is 4564.T stock a buy after the dip?

Given negative earnings, premium valuation, and model downside to **JPY 17.31**, Meyka AI currently suggests a HOLD. Active traders may use tight risk controls around trial news and liquidity.

JP Stocks

4564.T OncoTherapy Science (JPX) down 8.70% pre-market 24 Mar 2026: active volume insight

ByHuzaifa Zahoor March 23, 2026March 23, 2026

Pre-market trading shows 4564.T stock at JPY 21.00, down -8.70% on heavy volume of 66,352,100.00 shares on the JPX in Japan. This sharp move makes OncoTherapy Science, Inc. one of the most active names in the pre-market session on 24 Mar 2026. Market participants are pricing clinical and liquidity factors, with the stock trading below its 200-day average JPY 23.90 and above the year low JPY 19.00. We track fundamentals, technicals, and Meyka AI signals to explain the trade and near-term outlook.